Thomas James Doyle

CIK: 0001910331

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)12 (70.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (29.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KURA

Kura Oncology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

KURA
Kura Oncology, Inc.
Sep 28, 2026
Sale(S)
Direct
4.6K shares at avg. $10.50$48K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
2.2K shares at avg. $8.46$19K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
881 shares at avg. $8.46$7K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
2.2K shares at avg. $8.46$19K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
695 shares at avg. $8.46$6K
KURA
Kura Oncology, Inc.
Jan 27, 2026
Sale(S)
Direct
1.1K shares at avg. $8.46$9K
KURA
Kura Oncology, Inc.
Jan 2, 2026
Award(A)
Direct
21.3K shares-
KURA
Kura Oncology, Inc.
Nov 14, 2025
Sale(S)
Direct
4.5K shares at avg. $11.18$51K
KURA
Kura Oncology, Inc.
Nov 13, 2025
Award(A)
Direct
25K shares-
KURA
Kura Oncology, Inc.
Sep 29, 2025
Sale(S)
Direct
4.5K shares at avg. $8.94$41K
KURA
Kura Oncology, Inc.
Sep 27, 2025
Award(A)
Direct
25K shares-
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
2.2K shares at avg. $7.87$18K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
1.1K shares at avg. $7.87$9K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
699 shares at avg. $7.87$6K
KURA
Kura Oncology, Inc.
Jan 28, 2025
Sale(S)
Direct
887 shares at avg. $7.87$7K
KURA
Kura Oncology, Inc.
Jan 2, 2025
Award(A)
Direct
21.3K shares-
KURA
Kura Oncology, Inc.
Jan 2, 2025
Award(A)
Direct
21.3K shares-

		Type	Shares	Price		Ownership
Sep 28, 2026	KURA Kura Oncology, Inc.	Sale(S)	4,607	$10.50	$48,361	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	2,226	$8.46	$18,834	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	881	$8.46	$7,454	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	2,226	$8.46	$18,834	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	695	$8.46	$5,880	Direct
Jan 27, 2026	KURA Kura Oncology, Inc.	Sale(S)	1,114	$8.46	$9,425	Direct
Jan 2, 2026	KURA Kura Oncology, Inc.	Award(A)	21,250	-	$0	Direct
Nov 14, 2025	KURA Kura Oncology, Inc.	Sale(S)	4,539	$11.18	$50,732	Direct
Nov 13, 2025	KURA Kura Oncology, Inc.	Award(A)	24,967	-	-	Direct
Sep 29, 2025	KURA Kura Oncology, Inc.	Sale(S)	4,541	$8.94	$40,607	Direct
Sep 27, 2025	KURA Kura Oncology, Inc.	Award(A)	24,966	-	-	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	2,241	$7.87	$17,641	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	1,122	$7.87	$8,832	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	699	$7.87	$5,502	Direct
Jan 28, 2025	KURA Kura Oncology, Inc.	Sale(S)	887	$7.87	$6,982	Direct
Jan 2, 2025	KURA Kura Oncology, Inc.	Award(A)	21,250	-	$0	Direct
Jan 2, 2025	KURA Kura Oncology, Inc.	Award(A)	21,250	-	$0	Direct

1-17 of 17 transactions

About DOYLE THOMAS JAMES

DOYLE THOMAS JAMES (SEC CIK 0001910331) files insider reports with the SEC as SVP, Finance & Accounting of Kura Oncology, Inc. (KURA).

Signal8 holds 7 ownership filings by DOYLE THOMAS JAMES, all Form 4s, filed between Jan 6, 2025 and Sep 29, 2026. Those filings report 17 transactions, from Jan 2, 2025 to Sep 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DOYLE THOMAS JAMES's filings is in SAN DIEGO, CA.

Recent filings by DOYLE THOMAS JAMES

Sep 28, 2026: Open-market sale of KURA shares (Form 4, code S).
Jan 27, 2026: Open-market sales of KURA shares (5 lines, Form 4, code S).
Jan 2, 2026: Grant or award of KURA shares (Form 4, code A).
Nov 14, 2025: Open-market sale of KURA shares (Form 4, code S).
Nov 13, 2025: Grant or award of KURA shares (Form 4, code A).

Other insiders filing for Kura Oncology, Inc. (KURA)

Bair Teresa Brophy, Chief Legal Officer
FORD KATHLEEN, Chief Operating Officer
Leoni Mollie, Chief Medical Officer
Powl Brian T., Chief Commercial Officer
Burrows Francis, Chief Scientific Officer
Fulk Jennifer, Chief Financial Officer

How to read Form 4 transaction codes